AI Article Synopsis
Article Abstract
Background: Several neurologic complications have been reported in close temporal association with both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and following vaccination against SARS-CoV-2. Specifically, several cases of Guillain-Barré syndrome (GBS) have been reported in temporal relationship with COVID-19 vaccination, with two small case series describing a specific phenotype with bifacial weakness and paresthesia in the limbs.
Methods: We retrospectively collected patients who developed a new-onset neuromuscular disorder in the first 6 weeks after receiving a COVID-19 vaccine (either first or second dose). The patients were collected from one tertiary care centre and one secondary care centre from February to July 2021.
Results: We report eight patients who developed phenotypically diverse neuromuscular disorders in the weeks following COVID-19 vaccination, with a presumed immune-mediated etiology. In our case series, we report three patients with classical GBS, one patient with bifacial weakness with paresthesia variant of GBS, two patients with subacute-onset chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with brachial plexopathy and one patient with subacute axonal sensorimotor polyneuropathy.
Conclusions: New-onset neuromuscular disorders with onset in the weeks after COVID-19 vaccination can include diverse phenotypes. A causal relationship between these disorders and the vaccine cannot be proven at present, and further epidemiological studies are needed to further investigate this association.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059449 | PMC |
| http://dx.doi.org/10.1007/s13760-022-01941-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Age-structured modeling of COVID-19 dynamics: the role of treatment and vaccination in controlling the pandemic.
J Math Biol
December 2024
Complex Systems Research Center, Shanxi University, Taiyuan, 030006, Shanxi, China.
In addition to non-pharmaceutical interventions, antiviral drugs and vaccination are considered as the optimal solutions to control and eliminate the COVID-19 pandemic. It is necessary to couple within-host and between-host models to investigate the impact of treatment and vaccination. Hence, we propose an age-structured model, where the infection age is used to link the within-host viral dynamics and the disease dynamics at the population level.
View Article and Find Full Text PDFBooster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults.
Front Immunol
December 2024
Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Age-associated differences in the effect of repetitive vaccination, particularly on memory T-cell and B-cell responses, remain unclear. While older adults (aged ≥65 years) exhibited enhanced IgG responses following COVID-19 mRNA booster vaccination, they produced fewer spike-specific circulating follicular helper T cells-1 than younger adults. Similarly, the cytotoxic CD8 T-cell response remained diminished with reduced PD-1 expression even after booster vaccination compared with that in younger adults, suggesting impaired memory T-cell activation in older adults.
View Article and Find Full Text PDFEditorial: Cross-reactive immunity and COVID-19.
Front Immunol
December 2024
Dpto de Immunologia, Facultad de Medicina, U. Complutense de Madrid, Madrid, Spain.
Development of a prediction nomogram for IgG levels among asymptomatic or mild patients with COVID-19.
Front Cell Infect Microbiol
December 2024
Department of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Objective: COVID-19 has evolved into a seasonal coronavirus disease, characterized by prolonged infection duration and repeated infections, significantly increasing the risk of patients developing long COVID. Our research focused on the immune responses in asymptomatic and mild cases, particularly the critical factors influencing serum immunoglobulin G (IgG) levels and their predictive value.
Methods: We conducted a retrospective analysis on data from 1939 asymptomatic or mildly symptomatic COVID-19 patients hospitalized between September 2022 and June 2023.
COVID-19 Pandemic and its Impact on Vaccine Hesitancy: A Review.
Oman Med J
July 2024
Postgraduate School of Molecular Medicine, Erasmus MC-University Medical Center, Rotterdam, The Netherlands.
Vaccination is one of the most successful public health initiatives in human history, significantly reducing the incidence and severity of infectious diseases. The success of any vaccination program depends on several factors, including effective leadership, funding, distribution management, and addressing vaccine hesitancy. Vaccine hesitancy, the delay or refusal to be vaccinated despite the availability of immunization services, has always been prevalent in societies but has become more pronounced during the COVID-19 pandemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!